Mustang Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)											12 Months Ended
	Jan. 01, 2024 shares	Dec. 12, 2023 USD ($)	Oct. 30, 2023 USD ($)	Oct. 26, 2023 $ / shares shares	Mar. 15, 2023 shares	Jan. 01, 2023 shares	May 24, 2021 USD ($)	Dec. 04, 2019 USD ($)	Jul. 26, 2016 shares	Jul. 22, 2016	Dec. 31, 2023 USD ($) item $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 03, 2023 $ / shares	Dec. 31, 2021 $ / shares	Jul. 13, 2018	Dec. 31, 2016 USD ($) shares
Stockholders' Equity
Sale of Stock aggregate offering price - Founders Agreement \| $											$ 4,400,000
Preferred stock par value (in dollars per share) \| $ / shares											$ 0.0001	$ 0.0001	$ 0.0001
Number of fractional shares issued in connection with the Reverse Stock Split					0
Preferred stock, shares issued											250,000	250,000
Par value \| $											$ 591,000	$ 1,109,000
Common stock issuable - Annual Stock Dividend \| $											477,000	1,109,000
Shares issued for services (in shares)						187,134
Research and development for licenses acquired \| $											$ 527,000	$ 1,474,000
Common stock, shares issuable											419,089	187,134
Common stock, par value per share \| $ / shares											$ 0.0001	$ 0.0001
Exercise price of warrant \| $ / shares														$ 120.30
Shares available for future sale											380,089
At the Market Offering
Stockholders' Equity
Agent commission (as a percent)															3.00%
Issuance of common shares (in shares)											52,000	500,000
Shares issued, price per share \| $ / shares											$ 3.15	$ 12.61
Proceeds from issuance of common shares \| $											$ 163,000	$ 6,600,000
Aggregate fees of stock issuance \| $											3,000	100,000
Proceeds from issuance of Common Stock, net of offering costs \| $											160,000	$ 6,500,000
Registration Statements
Stockholders' Equity
Number of shares issuable upon exercise of warrants shares \| $		$ 2,743,530
Shelf Registration statement, value of securities authorized to be sold \| $								$ 100,000,000.0
Amount for issued and sale of registered direct offering \| $			$ 4,400,000								$ 195,600,000
Issuance of common shares (in shares)				920,000
Shares issued, price per share \| $ / shares				$ 1.70
Aggregate fees of stock issuance \| $			$ 500,000
Common stock, par value per share \| $ / shares				$ 0.0001
Total number of securities , warrant to be converted				1,668,236
Price per warrant \| $ / shares				$ 1.699
Difference in price of common stock and pre-funded warrant \| $ / shares				0.001
Exercise price of warrant \| $ / shares				$ 0.001
Registration Statements \| Maximum
Stockholders' Equity
Shelf Registration statement, value of securities authorized to be sold \| $							$ 200,000,000.0
Private Placement
Stockholders' Equity
Total number of securities , warrant to be converted				2,588,236
Price per warrant \| $ / shares				$ 0.125
Exercise price of warrant \| $ / shares				$ 1.58
Number of common stock, each warrant get converted				1
Warrants expiration term				5 years 6 months
Common Stock [Member]
Stockholders' Equity
Number of votes per share \| item											1
Class A Common Shares [Member]
Stockholders' Equity
Director appointment right, period											10 years
Preferred Class A [Member]
Stockholders' Equity
Preferred stock, shares issued												250,000
Prefunded Warrants
Stockholders' Equity
Total number of securities , warrant to be converted											1,668,236
Unregistered Warrants
Stockholders' Equity
Total number of securities , warrant to be converted											2,588,236
Placement Agents Warrants
Stockholders' Equity
Total number of securities , warrant to be converted											155,294
Fortress Biotech, Inc [Member]
Stockholders' Equity
Sale of Stock aggregate offering price - Founders Agreement \| $											$ 200,000	$ 6,600,000
Par value \| $																$ 900
Percentage of fully diluted equity	2.50%					2.50%					2.50%	2.50%
Common stock issuable - Annual Stock Dividend \| $											$ 353,086	$ 187,134
Shares issued for services (in shares)	353,086										66,003	13,131
Research and development for licenses acquired \| $											$ 500,000	$ 1,100,000
Issuance of common shares (in shares)												13,131
Shares issued, price per share \| $ / shares												$ 13.56
Common stock, shares issuable											1,297
Proceeds from issuance of common shares \| $											$ 200,000	$ 6,600,000
Shares Issuable \| $											$ 64,706
Stock dividend (as a percent)									2.50%
Fortress Biotech, Inc [Member] \| At the Market Offering
Stockholders' Equity
Issuance of common shares (in shares)											1,297	13,131
Shares issued, price per share \| $ / shares												$ 13.56
Proceeds from issuance of common shares \| $											$ 4,400,000
Fortress Biotech, Inc [Member] \| Common Stock [Member]
Stockholders' Equity
Common stock, shares issuable																2,000,000
Fortress Biotech, Inc [Member] \| Class B Common Shares [Member]
Stockholders' Equity
Number of shares converted									7,250,000
Common stock, shares issuable																7,000,000
Fortress Biotech, Inc [Member] \| Preferred Class A [Member]
Stockholders' Equity
Percentage of fully diluted equity										2.50%
Number of shares issued in conversion									250,000